“Top 15” List Predicts Best-Selling Cancer Drugs in 2022

Monoclonal antibodies remain popular

FiercePharma has compiled a list of the top 15 cancer medications that are expected to dominate the oncology market in 2022. According to the report, oncology drugs remain the fastest-growing category in pharma, with anticipated sales of approximately $90 billion over the next five years.

Among the top six drugs on the list, three are from the highly touted programmed death-1/programmed death ligand-1 (PD-1/PD-L1) or checkpoint inhibitor class. Drugs in this class activate the immune system, enabling it to recognize cancer cells and destroy them.

However, while the checkpoint inhibitor class has ascended, nine of the 15 top-selling drugs in 2022 will still be monoclonal antibodies, FiercePharma predicts. First approved in the late 1990s, these therapies quickly became the preferred option for various cancers. Three of them—all first-generation cancer antibodies from Roche—are due to face biosimilar competition within the next couple of years.

Here are the 15 drugs that FiercePharma foresees as being the dominant players on the oncology scene in 2022:

Revlimid (lenalidomide, Celgene): Thalidomide analogue. Current indications: multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. New indications, including newly diagnosed multiple myeloma and non-Hodgkin’s lymphoma, are expected in the near future.
Opdivo (nivolumab, Bristol-Myers Squibb): PD-1 inhibitor. Current indications: non–small-cell lung cancer (NSCLC), metastatic melanoma, renal cell carcinoma, and classical Hodgkin’s lymphoma.
Imbruvica (ibrutinib, Pharmacyclics/Janssen): Kinase inhibitor. Current indications: chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenström macroglobulinemia.
Keytruda (pembrolizumab, Merck): PD-1/PD-L1 inhibitor. Current indications: advanced melanoma, NSCLC, and head-and-neck squamous cell cancer.
Ibrance (palbociclib, Pfizer): Kinase inhibitor. Current indication: metastatic breast cancer.
Tecentriq (atezolizumab, Roche): PD-L1 inhibitor. Current indications: urothelial carcinoma and NSCLC.
Darzalex (daratumumab, Johnson & Johnson): CD38-directed cytolytic antibody. Current indication: multiple myeloma.
Perjeta (pertuzumab, Roche): Human epidermal growth factor receptor 2 (HER2)/neu receptor antagonist (antibody). Current indication: HER2-positive breast cancer.
Xtandi (enzalutamide, Astellas Pharma/Pfizer): Androgen receptor inhibitor. Current indication: advanced prostate cancer.
Avastin (bevacizumab, Genentech): Vascular endothelial growth factor-specific angiogenesis inhibitor (antibody). Current indications: colorectal cancer, NSCLC, ovarian cancer, cervical cancer, renal cell carcinoma, and glioblastoma.
Herceptin (trastuzumab, Genentech): HER2/neu receptor antagonist (antibody). Current indications: breast cancer and gastric cancer.
Gazyva (obinutuzumab, Genentech): CD20-directed cytolytic antibody. Current indications: CLL and follicular lymphoma.
Jakafi (ruxolitinib, Incyte/Novartis): Kinase inhibitor. Current indications: polycythemia vera and myelofibrosis.
Venclexta (venetoclax, AbbVie/Genentech): BCL-2 inhibitor (antibody). Current indication: CLL.
Rituxan (rituximab, Genentech): CD20-directed cytolytic antibody. Current indications: CLL and non-Hodgkin’s lymphoma.

Source: FiercePharma (link is external); January 17, 2017.

Inhaltsverzeichnis Anzeigen

More Headlines

Infliximab Biosimilar Is Noninferior to Remicade in Phase 3 Crohn’s Disease Study

Treatments show similar efficacy, safety, and tolerability profiles

Gleevec Provides Long-Term Survival in GIST Patients

Follow-up data published from nine-year-old study

Antimicrobial Soaps Do More Harm Than Good in Fight Against “Superbugs,” Scientist Says

Triclosan is primary culprit

Study: Prescription-Drug Monitoring Cuts Doctor-Shopping for Painkillers

State-run databases track prescribing of controlled substances

GOP to Revive High-Risk Pools in Obamacare Repeal

“Sickest of the sick” lead health care spending

Another Alzheimer’s Drug Bites the Dust

Committee sees “virtually no chance” of a positive effect

Study: Valium No Better Than Placebo for Lower Back Pain in the ED

“Magic bullet” remains elusive

Oral Ozanimod Shows Efficacy, Safety in Phase 3 Relapsing MS Trial

Annualized relapse rate reduced compared with interferon beta-1a

New Method Could Fast-Track Existing Drugs as Novel Treatments for Depression

Researchers utilize gene activity signatures to identify candidates

Well, they’ve defied expectations so far. It was expected that MA enrollment would decline from 10.9 million enrollees (or 24% of all Medicare enrollment) to 8.2 million (15% of Medicare’s total enrollment). Instead, enrollment has continued to climb. In 2016, 17.6 million Medicare beneficiaries—or 31% of all beneficiaries—were in MA plans.

The Missing Ingredient In Quality Measurement

The measures most often used today to assess care quality are process measures. Actual outcomes, of course, are harder to measure than whether a certain action has been taken—checking the feet of a patient with diabetes, for example. But many experts don’t think process measures get at the heart of quality.

HEDIS Is the Hassle That Became a Habit

After 25 years, the Healthcare Effectiveness Data and Information Set (HEDIS) is still criticized for focusing on process and taking up doctors’ time. But it has been incorporated into physicians’ workflow and may yet be instrumental in bringing about value-based care.

The reviews are in! CMS Rating of Hospitals Gets 1.5 Stars

The problem, say hospitals and some analysts, is that rating hospital quality is not so straightforward. How a hospital delivers care is multifactorial and complex, they argue, so trying to cram that into a single score is misleading and can end up like rating a restaurant on its parking.

Is Step Therapy a Move In the Wrong Direction?

If insurers insist that doctors use older, lower-cost drugs first, the burden is on the health plan to respond to doctors’ request for different medications quickly, nimbly, and appropriately. But quick and nimble do not often describe insurers’ step-therapy efforts.

Joint Venture Health Plans May Give ACOs a Run for Their Money

Joint venture plans are starting to demonstrate their ability to implement clinical management and financial management reforms. A JV health plan replaces the offloading of financial risk by health plans to ill-equipped providers with an executive-level cost management committee stated jointly by the hospital and payer.

Integrated Plans Fertile for Real-world Evidence

But most insurers are taking a wait-and-see attitude even though in some clinical areas, such as diabetes, real-world evidence (RWE) has been a true game-changer. Payers have a pessimistic view that RWE can help them. It doesn’t help that respected voices in health care agree.

For ED, the Doctor Is in But the Men Are Staying Away

Men’s health care changed dramatically after the FDA approved Pfizer’s blue, diamond-shaped Viagra. Suddenly men were interested in seeing their doctors if for only one reason. Now, with restrictions on what some call a lifestyle drug, other health problems go uncharted.

Fake Doctor Roams Boston Hospital

For several days, a middle-aged woman who claimed to be a doctor in training roamed the halls of Brigham and Women’s Hospital in Boston, dressed in scrubs, asking questions at a lecture, attending patient rounds, and observing surgical procedures, according to a report in the Boston Globe

Dire Side Effects Come With Immunotherapy

Immunotherapy causes the body to attack cancer, but it doesn’t stop there in some cases. It also turns on healthy tissue in the pancreas, kidneys, bowel, liver, lungs, and heart. These are life-threatening developments that force physicians to weigh the benefits of these “miracle drugs.”

Paul Lendner

Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.

More Headlines

Read Next